# Immuno Oncology Market

> Immuno-Oncology Market Research Report: Size, Share, Trend Analysis By Cancer Type (Lung Cancer, Melanoma, Breast Cancer, Colorectal Cancer, Leukemia, Lymphoma), By Treatment Modality (Checkpoint Inhibitors, Adoptive Cell Therapy, Cancer Vaccines, Oncolytic Viruses, Targeted Therapies), By Biomarker Type (PD-1, PD-L1, CTLA-4, LAG-3, TIM-3, IDO), By Combination Therapies (Checkpoint Inhibitor Combinations, Checkpoint Inhibitors and Targeted Therapies, Checkpoint Inhibitors and Immunotherapy, Targeted Therapy Combinations), By Disease Stage (Early Stage, Advanced Stage, Metastatic Disease) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 9.28%
- **2024:** $ 125.69 Billion
- **2025:** $ 137.36 Billion
- **2035:** $ 333.7 Billion
- **Key Players:** Bristol-Myers Squibb (US), Merck & Co. (US), Roche (CH), AstraZeneca (GB), Novartis (CH), Pfizer (US), Gilead Sciences (US), Eli Lilly and Company (US), Amgen (US)

**Report ID:** MRFR/HC/35962-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** June 08, 2026

**URL:** https://www.marketresearchfuture.com/reports/immuno-oncology-market-37917

---

## Market Summary

## **Immuno-oncology Market Overview**

As per MRFR analysis, the Immuno-Oncology Market Size was estimated at 125.69 (USD Billion) in 2024. The Immuno-Oncology Market Industry is expected to grow from 137.36 (USD Billion) in 2025 to 305.35 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 9.28% during the forecast period (2025 - 2034).

### **Key Immuno-oncology Market Trends Highlighted**

The Immuno-Oncology Market is driven by several key factors: rising cancer incidence, increasing adoption of immunotherapies, technological advancements, growing awareness about immuno-oncology, and government initiatives.

The rising prevalence of cancer and the growing demand for effective cancer therapies are major drivers of the market. Over the past few years, immunotherapies have gained significant traction due to their ability to enhance the body's immune response against cancer cells.

In recent years, the market has witnessed advancements in targeted therapies, such as the development of CAR T-cell therapies and bispecific antibodies, which offer personalized treatments with improved efficacy.

Moreover, increasing research and development efforts are leading to a growing pipeline of novel immuno-oncology agents, creating opportunities for market growth.

Another significant trend is the growing emphasis on combination therapies, where immuno-oncology drugs are combined with other modalities, such as chemotherapy or radiation therapy, to enhance treatment outcomes. This approach has demonstrated promising results in clinical trials and is expected to drive market growth.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Immuno-oncology Market Drivers**

### **Technological Advancements in Cancer Treatment**

Immuno-oncology is a fast-growing field, with new technologies being developed all the time. These technologies allow for more effective treatment of cancer with fewer side effects, and as a result, the Immuno-Oncology Market is growing at an increasing pace.

The most important technological advancement in immuno-oncology is the development of new immunotherapies, in particular, CAR T-cell therapy and immune checkpoint inhibitors. These therapies are now being used to treat a variety of cancers.

While there are still many challenges to be overcome, they are likely to become an increasingly important part of cancer treatment in the coming years. Another important trend that has contributed to the growth in demand for immuno-oncology technologies is the development of new diagnostic tools, which can identify the patients most likely to benefit from immunotherapy.

The growth of the sector is aided by the increasing incidence of cancer, increasing use of personalized medicine and advancements in immuno-oncology. In addition, the increasing uptake of immunotherapy, particularly by governments supported by supportive government initiatives and research studies, is driving the Immuno-Oncology Market.

### **Rising Prevalence of Cancer**

One of the key growth drivers of the Immuno-Oncology Market is the increasing prevalence of cancer. According to the World Health Organization, cancer is the first leading cause of death globally. There were about 19,300,000 new cases and 10,000,000 deaths in the world in 2020.

In addition, about 1 in 5 men and 1 in 6 women develop cancer at some point in their lives. Due to population growth, rapid urbanization, and aging of the population, the total number of cancer cases is expected to increase in the future, choosing the appropriate citation.

Again, many population-based studies have reported a rise in cancer incidence or prevalence because of lifestyle or behavioral changes.'].'. During the last decade, the increase in the prevalence of cancer has increased the need for a more effective anti-cancer treatment, which has facilitated the growth of the immuno-oncology market and the development and adoption of new immuno-oncology therapies.

### **Increasing Demand for Personalized Medicine**

Another factor that contributes to the development of the Immuno-Oncology Market is the increasing demand for personalized medicine. Personalized medicine is an administration technique that customizes medical products and practices to individual patients.

More and more the concept of personalized medicine becomes increasingly important to the treatment of malignant tumors. Approximately every cancer patient may have their own individual personalized medicine.

Immuno-oncology therapies are well adapted for conducting personalized medicine as they may be tailored on the basis of the genetic characteristics of each patient.

## **Immuno-Oncology Market Segment Insights**

### **Immuno-Oncology Market Cancer Type Insights**

The Immuno-Oncology Market, particularly concerning the Cancer Type segment, played a vital role in the overall growth of the industry.

Lung Cancer led this segment with a remarkable valuation of 40.0 USD Billion in 2023 and is projected to nearly double to 90.0 USD Billion by 2032, largely due to the high prevalence rates and the increasing emphasis on targeted and personalized therapies.

Following closely, Melanoma stood at a market valuation of 30.0 USD Billion in 2023, anticipated to rise to 65.0 USD Billion, which highlighted its growing importance as innovative treatments emerge, addressing the underlying genetics of this aggressive skin cancer.

[Breast Cancer](../../../reports/global-breast-cancer-market-1379), with a value of 20.0 USD Billion in 2023, was also on a strong upward trajectory towards 50.0 USD Billion by 2032. This increase reflected the significant focus on immunotherapy in addressing various subtypes of breast cancer as therapies continue to evolve and gain regulatory approvals.

Colorectal Cancer, regarded as a common yet often under-focused area, held a market valuation of 10.0 USD Billion in 2023, with an expected rise to 20.0 USD Billion, indicating steady growth amidst increasing awareness and advancements in diagnostics and treatment strategies.

Similarly, Leukemia, despite being less prevalent overall, commanded a value of 5.25 USD Billion in 2023 and is projected to reach 8.8 USD Billion by 2032, driven by the demand for innovative therapies and targeted treatments.

Lastly, Lymphoma, while not separately valued here, played an essential part in the Cancer Type segment with the constant evolution of immunotherapy options enhancing the treatment landscape.

This overall segmentation within the Immuno-Oncology Market highlighted existing revenue streams while also pointing toward future growth opportunities driven by ongoing research and development, increasing patient demand for effective treatment options, and a persistent push for innovative solutions across these cancer types.

The importance of these cancer types in the Immuno-Oncology framework showcases a robust trajectory of market growth influenced by the dual forces of medical innovation and the pressing need for effective cancer treatments.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Immuno-Oncology Market Treatment Modality Insights**

The segment encompasses various approaches, including Checkpoint Inhibitors, which have gained traction due to their ability to enhance the immune response against tumors, making them a cornerstone of immuno-oncology.

Adoptive Cell Therapy is also pivotal as it utilizes the patient's immune cells, demonstrating high efficacy in certain cancer types. Cancer Vaccines represent another crucial area, providing a proactive avenue for cancer prevention and management by stimulating the body's immune response to fight against malignancies.

Oncolytic Viruses harness the ability to selectively infect and destroy cancer cells, presenting innovative therapeutic potential. Additionally, Targeted Therapies have become significant as they offer personalized treatment options based on specific genetic markers.

The evolving landscape of the Immuno-Oncology Market segmentation reveals robust trends, with continuous advancements in research and development seen as key growth drivers. However, challenges such as high treatment costs and regulatory hurdles remain evident, creating both obstacles and opportunities within this dynamically growing field.

### **Immuno-Oncology Market Biomarker Type Insights**

The segment plays a crucial role in the development of targeted therapies, with various biomarkers like PD-1 and PD-L1 leading the market due to their significant role in cancer treatment.

These biomarkers facilitate the identification of patients who are more likely to respond to immune checkpoint inhibitors, ensuring more effective treatment protocols. CTLA-4, meanwhile, is integral in modulating the immune response against tumors, further driving market demand.

Other important biomarkers such as LAG-3, TIM-3, and IDO are emerging, offering promising prospects for enhancing treatment strategies and patient outcomes.

As the Immuno-Oncology Market data suggests, advancements in biomarker discovery and personalization of therapy are key trends fueling market growth, all while grappling with challenges like regulatory hurdles and the need for extensive clinical testing.

The increasing emphasis on precision medicine creates opportunities for innovation in the biomarker-type segment, aligning with the overall market strategy toward more effective and tailored oncology therapies.

### **Immuno-Oncology Market Combination Therapies Insights**

The Combination Therapies segment of the Immuno-Oncology Market is a robust area with considerable importance. This segment encapsulates various strategies that enhance treatment efficacy beyond monotherapy.

Checkpoint Inhibitor Combinations leverage the synergistic effects of multiple agents, leading to improved patient outcomes and higher response rates. Moreover, the pairing of Checkpoint Inhibitors and Targeted Therapies takes advantage of different mechanisms to combat cancer, making it a significant trend in cancer treatment.

Checkpoint Inhibitors and Immunotherapy form another crucial approach, as they activate the immune system while directly targeting tumor cells. Additionally, Targeted Therapy Combinations play a vital role by utilizing specific characteristics of cancer cells for effective treatment.

This diverse landscape within the Combination Therapies segment reflects a growing trend driven by the need for enhanced therapeutic options. Market growth is propelled by increasing research activities, the rising prevalence of cancers, and the shift towards personalized medicine.

Immuno-Oncology Market data reveals that these combination strategies are expected to address existing challenges in cancer treatment, offering numerous opportunities for pharmaceutical advancements and patient care.

### **Immuno-Oncology Market Disease Stage Insights**

The Immuno-Oncology Market has been experiencing robust growth, with a notable focus on the Disease Stage segment, which plays a crucial role in treatment outcomes.

The segmentation within the Disease Stage includes Early Stage, Advanced Stage, and Metastatic Disease, with each contributing significantly to the overall market dynamics. The Early Stage category is critical as it offers a higher potential for successful treatment and recovery, driving demand for immunotherapy options.

The Advanced Stage segment sees considerable investment due to the need for new therapies that can provide better outcomes for patients facing more aggressive diseases. Additionally, Metastatic Disease represents a significant portion of the market as it requires advanced treatment options, often yielding higher healthcare expenditure.

The Immuno-Oncology Market data demonstrates that as the understanding of cancer biology evolves, tailored therapies across these stages provide substantial growth opportunities while also posing challenges related to regulatory approvals and market access.

The interplay between these stages continues to shape market trends and drive the Immuno-Oncology Market statistics forward.

### **Immuno-Oncology Market Regional Insights**

North America dominated this space, holding a majority with a valuation of 58.0 USD Billion in 2023 and projected to reach 129.0 USD Billion by 2032, driven by advanced healthcare infrastructure and significant investments in research.

Europe followed as a significant player with a market value of 30.0 USD Billion in 2023, increasing to 70.0 USD Billion by 2032, indicative of robust regulatory frameworks supporting innovative therapies.

South America, while smaller in comparison with a valuation of 5.0 USD Billion, is expected to grow to 12.0 USD Billion, driven by increasing healthcare access and awareness. The Asia Pacific region was also on a growth trajectory, moving from 8.0 USD Billion to 15.0 USD Billion as the demand for advanced treatment options rose.

Meanwhile, the Middle East and Africa represented a niche market, valued at 4.25 USD Billion in 2023 and forecast to reach 7.8 USD Billion, presenting opportunities due to expanding healthcare initiatives. The data showed diverse regional dynamics within the Immuno-Oncology Market, with North America significantly leading the industry.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Immuno-oncology Market Key Players And Competitive Insights**

Innovative products and technology development remain the vital approach of the major players in the Immuno-oncology Market. In an attempt to gain a significant market position, the leading players in the Immuno-oncology Market are developing their market presence by concentrating on considerable partnerships with major market experiments, acquisitions, and mergers and expanding popular products.

Also, numerous promising candidates in the various stages of the clinical trials process can be witnessed in the Immuno-oncology Market development pipeline. Undeniably, it will significantly enhance the growth perspectives of the Immuno-oncology Market.

The prominent competitor in the Immuno-oncology Market can be observed to be the diversified group in the field, namely, Bristol-Myers Squibb. It can be seen that the company's portfolio of marketed drugs is undoubtedly strong. In the Immuno-oncology Market, the therapy that can be approved by the company is Opdivo.

Being a PD-1 inhibitor, it is mostly used to treat several types of cancer, including non-small-cell lung, squamous cell lung, melanoma, and renal cell. Yervoy, as a CTLA-4 inhibitor, is applicable for the melanoma treatment by the company.

Also, the activity of research and development of the company can be considered to be appealing. The numerous promising candidates of the Immuno-oncology Market in the company's portfolio in the various stages of the clinical trials process can be noticed.

Another major competitor in the Immuno-oncology Market is Merck Co. The company comprises the Immuno-oncology Market product Keytruda as a PD-1 inhibitor, which can be mostly used to treat non-small-cell lung and melanoma and also urinary bladder cancers.

Moreover, an attractive pipeline with several promising candidates can be found in the company in the various stages of the clinical trial process. The approach of Merck Co. to develop combination therapy based on the numerous Immuno-oncology Market mechanisms utilized to enhance the patient's condition can be noticed.

### **Key Companies in the Immuno-oncology Market Include**

- Incyte
- [Bristol Myers Squibb](https://www.bms.com/assets/bms/australia/documents/press-releases/Immuno-oncology%20Patient%20Resource.pdf)
- Gilead Sciences
- Roche
- Seagen
- Merck Co.
- Amgen
- EMD Serono
- AstraZeneca
- AbbVie
- Pfizer
- Celgene
- Ipsen
- Novartis
- BeiGene

### Immuno Oncology Market Industry Developments

- **Q2 2024: Merck’s Keytruda wins FDA approval for new lung cancer use** The U.S. FDA approved Merck’s immunotherapy Keytruda for use in combination with chemotherapy as a first-line treatment for certain patients with advanced or metastatic non-small cell lung cancer.
- **Q2 2024: Bristol Myers, BioNTech Announce Strategic Immuno-Oncology Partnership** Bristol Myers Squibb and BioNTech entered a multi-year partnership to co-develop and commercialize novel immuno-oncology therapies, focusing on next-generation checkpoint inhibitors and personalized cancer vaccines.
- **Q2 2024: Gilead Sciences Completes Acquisition of CymaBay Therapeutics** Gilead Sciences announced the completion of its acquisition of CymaBay Therapeutics, expanding its immuno-oncology pipeline with CymaBay’s investigational cancer immunotherapies.
- **Q2 2024: Immatics Announces $110 Million Private Placement Financing** Immatics N.V. raised $110 million in a private placement to advance its pipeline of TCR-based immuno-oncology therapies targeting solid tumors.
- **Q2 2024: AstraZeneca opens new $300M manufacturing facility for cancer immunotherapies** AstraZeneca inaugurated a new $300 million manufacturing facility dedicated to the production of immuno-oncology drugs, aiming to scale up supply for global markets.
- **Q3 2024: Moderna and Merck expand cancer vaccine collaboration with $250m investment** Moderna and Merck announced an expansion of their collaboration to develop and commercialize personalized cancer vaccines, with Merck investing an additional $250 million.
- **Q3 2024: Nektar Therapeutics Appoints New Chief Executive Officer** Nektar Therapeutics announced the appointment of a new CEO to lead the company’s strategic focus on immuno-oncology drug development.
- **Q3 2024: FDA approves Roche’s Tecentriq for early-stage lung cancer** The U.S. FDA approved Roche’s immunotherapy Tecentriq as an adjuvant treatment for certain patients with early-stage non-small cell lung cancer following surgery and chemotherapy.
- **Q3 2024: Novartis to acquire Chinook Therapeutics in $3.2 billion immuno-oncology deal** Novartis announced an agreement to acquire Chinook Therapeutics for $3.2 billion, strengthening its immuno-oncology portfolio with Chinook’s pipeline assets.
- **Q4 2024: Adaptimmune and Genentech Announce Strategic Collaboration to Develop Allogeneic Cell Therapies** Adaptimmune and Genentech entered a strategic collaboration to co-develop and commercialize allogeneic cell therapies for cancer, leveraging Adaptimmune’s TCR technology.
- **Q4 2024: Immunocore Announces FDA Approval of KIMMTRAK for Uveal Melanoma** Immunocore received FDA approval for KIMMTRAK, the first TCR-based immunotherapy for the treatment of unresectable or metastatic uveal melanoma.
- **Q1 2025: Pfizer launches new immuno-oncology research center in Boston** Pfizer opened a new research center in Boston focused on the discovery and development of next-generation immuno-oncology therapies.

## **Immuno-oncology Market Segmentation Insights**

### **Immuno-Oncology Market Cancer Type Outlook**

- Lung Cancer
- Melanoma
- Breast Cancer
- Colorectal Cancer
- Leukemia
- Lymphoma

### **Immuno-Oncology Market Treatment Modality Outlook**

- Checkpoint Inhibitors
- Adoptive Cell Therapy
- Cancer Vaccines
- Oncolytic Viruses
- Targeted Therapies

### **Immuno-Oncology Market Biomarker Type Outlook**

- PD-1
- PD-L1
- CTLA-4
- LAG-3
- TIM-3
- IDO

### **Immuno-Oncology Market Combination Therapies Outlook**

- Checkpoint Inhibitor Combinations
- Checkpoint Inhibitors and Targeted Therapies
- Checkpoint Inhibitors and Immunotherapy
- Targeted Therapy Combinations

### **Immuno-Oncology Market Disease Stage Outlook**

- Early Stage
- Advanced Stage
- Metastatic Disease

### **Immuno-Oncology Market Regional Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### Rising Incidence of Cancer

The increasing prevalence of cancer worldwide is a primary driver for the Immuno-Oncology Market. According to recent statistics, cancer cases are projected to rise significantly, with estimates suggesting that by 2025, there could be over 19 million new cancer cases annually. This alarming trend necessitates the development of innovative treatment options, thereby propelling the demand for immuno-oncology therapies. As healthcare systems strive to address this growing burden, investments in research and development of immuno-oncology products are likely to surge. The urgency to find effective treatments for various cancer types, including those that are traditionally hard to treat, underscores the critical role of the Immuno-Oncology Market in the broader healthcare landscape.

### Advancements in Research and Technology

Technological advancements in the field of immunotherapy are significantly influencing the Immuno-Oncology Market. Innovations in genetic engineering, such as CAR-T cell therapy, have shown promising results in treating certain cancers. Furthermore, the integration of artificial intelligence in drug discovery processes is streamlining the identification of potential immuno-oncology candidates. As a result, the market is witnessing a surge in novel therapies entering clinical trials, with a notable increase in the number of FDA approvals for immuno-oncology drugs. This trend indicates a robust pipeline of therapies that could transform treatment paradigms, thereby enhancing the growth prospects of the Immuno-Oncology Market.

### Increased Investment in Cancer Research

The Immuno-Oncology Market is experiencing a surge in investment from both public and private sectors. Governments and pharmaceutical companies are allocating substantial funds towards cancer research, particularly in immunotherapy. For instance, funding for cancer research initiatives has seen a marked increase, with billions of dollars being invested annually. This financial backing is crucial for advancing clinical trials and bringing innovative therapies to market. Additionally, partnerships between academic institutions and biotech firms are fostering collaborative research efforts, which are likely to yield breakthroughs in immuno-oncology treatments. Such investments not only enhance the development of new therapies but also solidify the Immuno-Oncology Market's position as a vital component of modern oncology.

### Growing Awareness and Acceptance of Immunotherapy

There is a notable increase in awareness and acceptance of immunotherapy among healthcare professionals and patients, which is positively impacting the Immuno-Oncology Market. Educational initiatives and successful case studies are helping to demystify immunotherapy, leading to greater confidence in its efficacy. As more patients seek out immuno-oncology treatments, healthcare providers are increasingly incorporating these therapies into standard treatment protocols. This shift in perception is likely to drive demand for immuno-oncology products, as patients become more informed about their treatment options. The growing acceptance of immunotherapy as a viable treatment modality is expected to further bolster the Immuno-Oncology Market in the coming years.

### Regulatory Support and Streamlined Approval Processes

Regulatory bodies are increasingly recognizing the potential of immuno-oncology therapies, leading to more streamlined approval processes within the Immuno-Oncology Market. Initiatives aimed at expediting the review of innovative cancer treatments are becoming more common, with agencies implementing programs that prioritize breakthrough therapies. This regulatory support is crucial for bringing new immuno-oncology products to market more quickly, thereby addressing urgent patient needs. As a result, the number of approved immuno-oncology therapies is likely to increase, fostering competition and innovation within the market. The favorable regulatory environment is expected to enhance the growth trajectory of the Immuno-Oncology Market, making it an attractive area for investment and development.

## Future Outlook

The Immuno-Oncology Market is projected to grow at a 9.28% CAGR from 2025 to 2035, driven by advancements in therapies, increasing cancer prevalence, and enhanced R&D investments.

**New opportunities:**

- Development of personalized immunotherapies targeting specific cancer mutations. Expansion of combination therapies integrating immuno-oncology with traditional treatments. Investment in digital health technologies for patient monitoring and engagement.

By 2035, the Immuno-Oncology Market is expected to be robust, driven by innovation and strategic partnerships.

## Segment Insights

### By Cancer Type: Lung Cancer (Largest) vs. Melanoma (Fastest-Growing)

The Immuno-Oncology Market shows a significant distribution of market share across various cancer types. Lung Cancer remains the largest segment, driven by increasing incidences and advancements in immunotherapies tailored specifically to target lung tumors. Melanoma is emerging strongly as a fast-growing segment, thanks to novel therapies and heightened awareness of skin cancer treatments. These developments contribute significantly to expanding immuno oncology market share and strengthening the overall immuno oncology market growth trajectory.

Lung Cancer (Dominant) vs. Melanoma (Emerging)

Lung Cancer is the dominant segment in the Immuno-Oncology Market, characterized by a range of established therapies that effectively target tumor microenvironments within the global immuno-oncology market. Continuous innovation in immunotherapies is further strengthening the immuno oncology market landscape. On the contrary, Melanoma presents an emerging opportunity driven by rapid development in immune checkpoint inhibitors and personalized medicine approaches. Clinicians are increasingly focusing on combination therapies to elevate treatment efficacy, increasing melanoma’s market relevance and positioning it for rapid growth alongside advanced research into underlying mechanisms.

### By Treatment Modality: Checkpoint Inhibitors (Largest) vs. Adoptive Cell Therapy (Fastest-Growing)

The Immuno-Oncology market reveals a multifaceted landscape with Checkpoint Inhibitors leading in market share. They dominate the segment by providing a cornerstone for cancer immunotherapy, enabling the immune system to recognize and attack cancer cells more effectively. Other modalities, like Adoptive Cell Therapy, Cancer Vaccines, Oncolytic Viruses, and Targeted Therapies, also contribute to the market but at varying levels of acceptance and adoption, illustrating a diverse portfolio of treatment options available to oncologists. Furthermore, growth trends indicate that while Checkpoint Inhibitors remain prevalent, Adoptive Cell Therapy is gaining traction rapidly due to technological advancements and clinical successes, contributing to positive immuno oncology market trends.. Emerging modalities such as Cancer Vaccines show potential, spurring research activities, while Oncolytic Viruses are noted for their innovative and unique mechanisms of action. The overall market is driven by the increasing prevalence of cancer, advances in biomedical research, and the need for personalized therapies.

Checkpoint Inhibitors (Dominant) vs. Cancer Vaccines (Emerging)

Checkpoint Inhibitors represent the dominant modality within the Immuno-Oncology market, known for their ability to unleash the immune system's capability to destroy tumors. In contrast, Cancer Vaccines, while classified as emerging, are gaining attention for their potential to provide long-lasting protection against cancer recurrence. Checkpoint Inhibitors, such as PD-1 and CTLA-4 inhibitors, have shown substantial efficacy in a range of cancers, creating a significant demand among oncologists. Conversely, Cancer Vaccines are undergoing revitalization through innovative approaches, including personalized and therapeutic vaccines that target specific tumor antigens. As research progresses, the potential for combination therapies involving these modalities may enhance treatment efficacy, paving the way for broader acceptance and integration into standard oncology practices.

### By Biomarker Type: PD-1 (Largest) vs. CTLA-4 (Fastest-Growing)

In the Immuno-Oncology Market, the biomarker type segment shows significant diversity in market share. PD-1 leads this segment as the largest biomarker, reflecting its robust application in numerous cancer therapies. Meanwhile, PD-L1 and CTLA-4 follow closely, offering substantial shares as key players in immunotherapy, while emerging biomarkers like LAG-3, TIM-3, and IDO are gradually gaining ground. Despite being smaller, these emerging markers indicate a shift toward a more personalized approach to oncology treatments, highlighting their growing significance in patient selection and therapeutic strategies. The growth trends within the biomarker type segment are indicative of an evolving landscape in Immuno-Oncology. PD-1 remains dominant due to its established role in checkpoint inhibition, bolstered by extensive research and clinical success. On the other hand, CTLA-4 is recognized as the fastest-growing biomarker, driven by increased approvals and combination therapies that enhance efficacy. This growth is supported by a heightened focus on precision medicine and the integration of novel biomarkers into clinical decision-making, which promises to transform treatment paradigms and improve patient outcomes.

PD-1 (Dominant) vs. LAG-3 (Emerging)

PD-1, as the dominant biomarker in the Immuno-Oncology Market, has become a cornerstone of cancer immunotherapy, proving its efficacy in various malignancies such as melanoma and lung cancer. Its success is reflected in numerous drug approvals and a solid pipeline of candidates. CD274, the ligand for PD-1, further illustrates the interplay of PD-L1 in combination therapies. Conversely, LAG-3, while still emerging, is gaining attention due to its unique mechanism that complements existing therapies. As research progresses, LAG-3 is showing potential in enhancing the efficacy of treatments, especially in combination with PD-1 inhibitors. This positioning marks it as a promising target for future therapies, signifying a shift in the landscape towards more nuanced and effective combinations that cater to individual patient needs.

### By Combination Therapies: Checkpoint Inhibitor Combinations (Largest) vs. Targeted Therapy Combinations (Fastest-Growing)

The Combination Therapies segment in the Immuno-Oncology Market is widely recognized for its diverse set of treatment options. Among these, Checkpoint Inhibitor Combinations hold the largest market share due to their proven efficacy and widespread adoption in various cancer types. Targeted Therapy Combinations are gaining significant traction as an emerging force, fueled by advancements in personalized medicine and precision therapeutics that complement traditional immunotherapy approaches.

Checkpoint Inhibitor Combinations (Dominant) vs. Targeted Therapy Combinations (Emerging)

Checkpoint Inhibitor Combinations are at the forefront of the Immuno-Oncology market, leveraging synergistic effects to enhance patient outcomes. These therapies, which include combinations of PD-1, PD-L1, and CTLA-4 inhibitors, have demonstrated significant clinical benefits, contributing to their dominant market position. Meanwhile, Targeted Therapy Combinations are emerging as key players, harnessing specific genetic mutations and molecular targets to improve the effectiveness and tolerability of treatments. As research progresses, both segments are expected to evolve, with Checkpoint Inhibitor Combinations remaining robust, while Targeted Therapy Combinations capture a growing share through innovative clinical trials and combination strategies.

### By Disease Stage: Advanced Stage (Largest) vs. Metastatic Disease (Fastest-Growing)

In the Immuno-Oncology market, the distribution among disease stages reveals that the Advanced Stage currently holds the largest market share, benefiting from robust treatment protocols and increasing clinical approvals. This stage encompasses various cancers that have progressed significantly, requiring more advanced therapeutic interventions, thereby dominating the overall segment. Meanwhile, the Metastatic Disease segment, which involves cancer that has spread beyond its original site, is rapidly gaining traction among healthcare providers and researchers as new therapies targeting this challenging stage are emerging.

Advanced Stage (Dominant) vs. Metastatic Disease (Emerging)

The Advanced Stage in the Immuno-Oncology market is characterized by its well-established therapies and a growing patient population seeking innovative treatments. This phase often incorporates combination therapies and immune checkpoint inhibitors tailored to combat resilient tumors. In contrast, the Metastatic Disease segment is emerging as a critical area of focus due to rising incidences of cancer metastasis, which poses significant challenges for treatment. Researchers are increasingly prioritizing the development of novel therapeutics aimed at addressing metastatic pathways, making this segment one of the fastest-growing areas within the market.

## Regional Market Share Analysis

North America dominated this space, holding a majority with a valuation of 58.0 USD Billion in 2023 and projected to reach 129.0 USD Billion by 2032, driven by advanced healthcare infrastructure and significant investments in research.

Europe followed as a significant player with a market value of 30.0 USD Billion in 2023, increasing to 70.0 USD Billion by 2032, indicative of robust regulatory frameworks supporting innovative therapies.

South America, while smaller in comparison with a valuation of 5.0 USD Billion, is expected to grow to 12.0 USD Billion, driven by increasing healthcare access and awareness. The Asia Pacific region was also on a growth trajectory, moving from 8.0 USD Billion to 15.0 USD Billion as the demand for advanced treatment options rose.

Meanwhile, the Middle East and Africa represented a niche market, valued at 4.25 USD Billion in 2023 and forecast to reach 7.8 USD Billion, presenting opportunities due to expanding healthcare initiatives. The data showed diverse regional dynamics within the Immuno-Oncology Market, with North America significantly leading the industry.

## Competitive Benchmarking

Innovative products and technology development remain the vital approach of the major players in the Immuno-oncology Market. In an attempt to gain a significant market position, the leading players in the Immuno-oncology Market are developing their market presence by concentrating on considerable partnerships with major market experiments, acquisitions, and mergers and expanding popular products. Also, numerous promising candidates in the various stages of the clinical trials process can be witnessed in the Immuno-oncology Market development pipeline. Undeniably, it will significantly enhance the growth perspectives of the Immuno-oncology Market. The prominent competitor in the Immuno-oncology Market can be observed to be the diversified group in the field, namely, Bristol-Myers Squibb. It can be seen that the company's portfolio of marketed drugs is undoubtedly strong. In the Immuno-oncology Market, the therapy that can be approved by the company is Opdivo. Being a PD-1 inhibitor, it is mostly used to treat several types of cancer, including non-small-cell lung, squamous cell lung, melanoma, and renal cell. Yervoy, as a CTLA-4 inhibitor, is applicable for the melanoma treatment by the company. Also, the activity of research and development of the company can be considered to be appealing. The numerous promising candidates of the Immuno-oncology Market in the company's portfolio in the various stages of the clinical trials process can be noticed. Another major competitor in the Immuno-oncology Market is Merck Co. The company comprises the Immuno-oncology Market product Keytruda as a PD-1 inhibitor, which can be mostly used to treat non-small-cell lung and melanoma and also urinary bladder cancers. Moreover, an attractive pipeline with several promising candidates can be found in the company in the various stages of the clinical trial process. The approach of Merck Co. to develop combination therapy based on the numerous Immuno-oncology Market mechanisms utilized to enhance the patient's condition can be noticed.

## Recent News & Developments

- **Q2 2024: Merck’s Keytruda wins FDA approval for new lung cancer use** The U.S. FDA approved Merck’s immunotherapy Keytruda for use in combination with chemotherapy as a first-line treatment for certain patients with advanced or metastatic non-small cell lung cancer.
- **Q2 2024: Bristol Myers, BioNTech Announce Strategic Immuno-Oncology Partnership** Bristol Myers Squibb and BioNTech entered a multi-year partnership to co-develop and commercialize novel immuno-oncology therapies, focusing on next-generation checkpoint inhibitors and personalized cancer vaccines.
- **Q2 2024: Gilead Sciences Completes Acquisition of CymaBay Therapeutics** Gilead Sciences announced the completion of its acquisition of CymaBay Therapeutics, expanding its immuno-oncology pipeline with CymaBay’s investigational cancer immunotherapies.
- **Q2 2024: Immatics Announces $110 Million Private Placement Financing** Immatics N.V. raised $110 million in a private placement to advance its pipeline of TCR-based immuno-oncology therapies targeting solid tumors.
- **Q2 2024: AstraZeneca opens new $300M manufacturing facility for cancer immunotherapies** AstraZeneca inaugurated a new $300 million manufacturing facility dedicated to the production of immuno-oncology drugs, aiming to scale up supply for global markets.
- **Q3 2024: Moderna and Merck expand cancer vaccine collaboration with $250m investment** Moderna and Merck announced an expansion of their collaboration to develop and commercialize personalized cancer vaccines, with Merck investing an additional $250 million.
- **Q3 2024: Nektar Therapeutics Appoints New Chief Executive Officer** Nektar Therapeutics announced the appointment of a new CEO to lead the company’s strategic focus on immuno-oncology drug development.
- **Q3 2024: FDA approves Roche’s Tecentriq for early-stage lung cancer** The U.S. FDA approved Roche’s immunotherapy Tecentriq as an adjuvant treatment for certain patients with early-stage non-small cell lung cancer following surgery and chemotherapy.
- **Q3 2024: Novartis to acquire Chinook Therapeutics in $3.2 billion immuno-oncology deal** Novartis announced an agreement to acquire Chinook Therapeutics for $3.2 billion, strengthening its immuno-oncology portfolio with Chinook’s pipeline assets.
- **Q4 2024: Adaptimmune and Genentech Announce Strategic Collaboration to Develop Allogeneic Cell Therapies** Adaptimmune and Genentech entered a strategic collaboration to co-develop and commercialize allogeneic cell therapies for cancer, leveraging Adaptimmune’s TCR technology.
- **Q4 2024: Immunocore Announces FDA Approval of KIMMTRAK for Uveal Melanoma** Immunocore received FDA approval for KIMMTRAK, the first TCR-based immunotherapy for the treatment of unresectable or metastatic uveal melanoma.
- **Q1 2025: Pfizer launches new immuno-oncology research center in Boston** Pfizer opened a new research center in Boston focused on the discovery and development of next-generation immuno-oncology therapies.

## Report Scope

| MARKET SIZE 2024 | 125.69(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 137.36(USD Billion) |
| MARKET SIZE 2035 | 333.7(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.28% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Bristol-Myers Squibb (US), Merck & Co. (US), Roche (CH), AstraZeneca (GB), Novartis (CH), Pfizer (US), Gilead Sciences (US), Eli Lilly and Company (US), Amgen (US) |
| Segments Covered | Cancer Type, Treatment Modality, Biomarker Type, Combination Therapies, Disease Stage, Regional |
| Key Market Opportunities | Advancements in personalized therapies and combination treatments drive growth in the Immuno-Oncology Market. |
| Key Market Dynamics | Rising demand for personalized therapies drives innovation and competition in the Immuno-Oncology Market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Immuno-Oncology Market as of 2024?**
A: The Immuno-Oncology Market was valued at 125.69 USD Billion in 2024.

**Q: What is the projected market size for the Immuno-Oncology Market by 2035?**
A: The market is projected to reach 333.7 USD Billion by 2035.

**Q: What is the expected CAGR for the Immuno-Oncology Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Immuno-Oncology Market during 2025 - 2035 is 9.28%.

**Q: Which cancer types are leading in market valuation within the Immuno-Oncology sector?**
A: Lung Cancer and Breast Cancer are leading, with valuations of 30.0 to 80.0 USD Billion and 25.0 to 70.0 USD Billion, respectively.

**Q: What are the key treatment modalities driving the Immuno-Oncology Market?**
A: Checkpoint Inhibitors dominate the market, with a valuation range of 45.0 to 120.0 USD Billion.

**Q: How do combination therapies impact the Immuno-Oncology Market?**
A: Combination therapies, particularly Targeted Therapy Combinations, are projected to reach 50.69 to 138.7 USD Billion.

**Q: Which biomarkers are most significant in the Immuno-Oncology Market?**
A: PD-L1 and PD-1 are significant biomarkers, with valuations ranging from 30.0 to 80.0 USD Billion and 25.0 to 70.0 USD Billion, respectively.

**Q: What role do key players like Bristol-Myers Squibb and Merck & Co. play in the market?**
A: Key players such as Bristol-Myers Squibb and Merck & Co. are instrumental in driving innovation and market growth.

**Q: What is the market outlook for advanced stage cancer treatments in Immuno-Oncology?**
A: Advanced stage cancer treatments are expected to grow significantly, with a projected valuation of 50.0 to 130.0 USD Billion.

**Q: How does the Immuno-Oncology Market compare across different disease stages?**
A: The market shows a strong focus on advanced and metastatic disease stages, with valuations of 50.0 to 130.0 USD Billion and 50.69 to 133.7 USD Billion, respectively.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/immuno-oncology-market-37917*